The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More
News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW. This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy. The top stories: Psychedelic drug could help treat depression … Read More
Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows. Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis… Read More
Amorphical has announced positive final long-term follow-up data from its Phase II clinical trial evaluating its investigational nano-amorphous Calcium Carbonate (ACC) therapy, for the treatment of moderate-to-severe Crohn’s disease. The full data analysis, including a cohort of patients who completed follow-up extending up to 48 weeks post-baseline,… Read More
The European Commission (EC) has granted marketing authorisation for the world’s first liquid formulation of infliximab. Remsima is an intravenous liquid formulation used to treat autoimmune diseases including Crohn’s disease and ulcerative colitis. Remsima was first approved in September 2013 and launched in major EU countries in 2015 as a… Read More
The Scottish Medicines Consortium (SMC) has accepted Tremfya (guselkumab) for use in NHS Scotland for the treatment of adult patients with moderately to severe Crohn’s disease and ulcerative colitis. Guselkumab is the first IL-23 inhibitor that could offer a fully subcutaneous induction and maintenance regimen in Crohn’s… Read More
The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease. The approval is based on data which showed that guselkumab induction therapy administered either intravenously… Read More
Redx Pharma has shared additional results from an RXC008 Phase I clinical trial at Digestive Disease Week 2025, San Diego, CA. RXC008 is a highly potent pan-Rho-associated coiled-coil kinase (pan-ROCK) inhibitor that was designed to be restricted to the gastrointestinal (GI) tract. The Phase I… Read More
Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD). The submission is based on results from the Phase III pivotal data that evaluated the efficacy and… Read More
A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease. The BIOPIC (BIOlogics and Partial enteral nutrition In adults with active ileocolonic Crohn’s disease) study, which is in collaboration with hospitals… Read More
Results of a new study by researchers at Case Western Reserve University represent a step toward improving understanding of Crohn’s disease and the factors that cause its intestinal inflammation. About Crohn’s disease Crohn’s disease is a type of inflammatory bowel disease that can lead… Read More
The Janssen Pharmaceutical Companies of Johnson & Johnson has released efficacy and safety data for STELARA (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, the first study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session. Read More
